Company / R&D Expense
OCULAR THERAPEUTIX, INC R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$197.1M
FY2025
5-year range
$28.7M / $197.1M
FY2021-FY2025
Trend
+54.4%
vs FY2024
Sector context
#83 of 210
Health Care
What the data says
At $197M, OCULAR THERAPEUTIX, INC's r&d expense ranks #83 of 210 in the Health Care sector. R&D Expense has increased for 3 consecutive years, from $29M in FY2022 to $197M in FY2025.
Based on SEC 10-K filings.
$197M in FY2025 with a 5-year CAGR of +36.8%.
Improved from $61M to $197M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +90.1%
- 5-Year CAGR
- +36.8%
- 10-Year CAGR
- -
Sector benchmark
#83 of 210 in Health CareTop 40% of 210This company $197.1M Sector average $644.0M
▼
-69.4% below sector average
Key checks
Key Insights
- OCULAR THERAPEUTIX, INC's r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +36.8%, indicating consistent growth.
- In FY2025, r&d expense increased 54.4% year-over-year.
- Ranks #83 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $197.1M | +54.4% |
| FY2024 | $127.6M | +109.0% |
| FY2023 | $61.1M | +112.8% |
| FY2022 | $28.7M | -30.2% |
| FY2021 | $41.1M | +0.0% |
| FY2020 | $41.1M | +33.1% |
| FY2019 | $30.9M | -16.3% |
| FY2018 | $36.9M | +19.5% |
| FY2017 | $30.9M | +14.1% |
| FY2016 | $27.1M | +157.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026